


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Clark Memorial Hospital</p> <p>2. 1220 Missouri Ave. Jeffersonville, IN 47130</p>		<p>In accordance with letters dated May 20, 2022, and June 10, 2022,</p>	<p>4. Expiration Date: March 31, 2025</p>
		<p>3. License No.: 13-12367-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01658 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p> <p>E. Strontium-90</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p> <p>E. Sealed Sources</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 2 millicuries total</p> <p>E. 100 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For use in in-vitro studies.</p> <p>E. For possession only, incident to disposal.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-12367-01

Docket or Reference No.:
030-01658

Amendment No. 46

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1220 Missouri Ave., Jeffersonville, Indiana, 47130.
11. The Radiation Safety Officer (RSO) for this license is Jeffrey Boyd, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Frederick Albrink, M.D.

10 CFR 35.300

Daniel Altman, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Laura Barkley, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Brett Batchelor, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Zulfiquar Bhatti, M.D.

10 CFR 35.100,10 CFR 35.200

D. Mark Bickers, M.D.

10 CFR 35.100,10 CFR 35.200

James W. Boyd, M.D.

10 CFR 35.100,10 CFR 35.200

Jeffrey Boyd, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Kelly J. Colomb, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Otis C. Colvin, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-12367-01

Docket or Reference No.:

030-01658

Amendment No. 46

Authorized User (M.D., D.O., etc.)Material and Use

Theresa Corrigan, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Bart Dawson, M.D.

10 CFR 35.100, 10 CFR 35.200

Christopher J. Day, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Dolph Martel Denny, M.D.

10 CFR 35.100, 10 CFR 35.200

Naveen Devabhaktuni, M.D.

10 CFR 35.100, 10 CFR 35.200

Scott M. Duncan, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Ibrahim Fahsah, M.D.

10 CFR 35.100, 10 CFR 35.200

Robert Falk, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Steve Filardo, M.D.

10 CFR 35.100, 10 CFR 35.200

Emily Folz, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Satya Garimella, M.D.

10 CFR 35.200

Wayne St. Michael Gibson, M.D.

10 CFR 35.200

Kendall Goldschmidt, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Bapineedu Gondi, M.D.

10 CFR 35.100, 10 CFR 35.200

Phong X. Ha, M.D.

10 CFR 35.100, 10 CFR 35.200

Lori Haycraft, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

David Damion Hazlett, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Lawrence Hochman, D.O.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries, and the parenteral administration of unsealed byproduct material requiring a written directive)

Christopher S. Hofelich, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-12367-01

Docket or Reference No.:

030-01658

Amendment No. 46

Authorized User (M.D.,D.O.,etc.)

Material and Use

Sohail Ikram, M.D.

10 CFR 35.100,10 CFR 35.200

Koduvathara James, M.D.

10 CFR 35.100,10 CFR 35.200

Eric A. Jones, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Craig S. Kamen, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Robert Keeling, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

John Terrence Kenny, M.D.

10 CFR 35.100,10 CFR 35.200

Mitchell Jay Kline, M.D.

10 CFR 35.100,10 CFR 35.200

J. Frederick Klink, III, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Ilana Kogan, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Frank E. Lee, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Srinivasarao Manchikalapudi, M.D.

10 CFR 35.100,10 CFR 35.200

Hans C. Mouser, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

David Musich, M.D.

10 CFR 31.11,10 CFR 35.300

Matthew Nett, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Thomas C. Passo, M.D.

10 CFR 35.100,10 CFR 35.200

Geoffrey Peters, M.D.

10 CFR 35.100,10 CFR 35.200

Zaka Ur Rahman, M.D.

10 CFR 35.100,10 CFR 35.200

Syed Raza, M.D.

10 CFR 35.200

Edsel S. Reed, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Ali Nawab Risvi, M.D.

10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-12367-01

Docket or Reference No.:

030-01658

Amendment No. 46

Authorized User (M.D., D.O., etc.)

Material and Use

David Rodriguez, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Paul J. Rogers, M.D.

10 CFR 35.100, 10 CFR 35.200

Armand Rothschild, M.D.

10 CFR 35.100, 10 CFR 35.200

Rodney A. Samaan, M.D.

10 CFR 35.200

William J. Schoen, M.D.

10 CFR 35.100, 10 CFR 35.200

Jerome Schrodt, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Kevin P. Serey, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Anil K. Sharma, M.D.

10 CFR 35.200

Wayne Shugoll, M.D.

10 CFR 35.100, 10 CFR 35.200

Igor Singer, M.D.

10 CFR 35.100, 10 CFR 35.200

Gurbachan Sohi, M.D.

10 CFR 35.100, 10 CFR 35.200

Naresh Solankhi, M.D.

10 CFR 35.100, 10 CFR 35.200

Barry S. Stevens, M.D.

10 CFR 35.100, 10 CFR 35.200

Mio Michael Stikovac, M.D.

10 CFR 35.200

Thomas Matthew Sweat, M.D.

10 CFR 35.100, 10 CFR 35.200

Richard Waggener, M.D.

10 CFR 35.100, 10 CFR 35.200

Andrea Walker, D.O.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Brian Worm, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jason Yewell, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Gary Yurow, M.D.

10 CFR 35.100, 10 CFR 35.200

Sara Zakel, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-12367-01

Docket or Reference No.:
030-01658

Amendment No. 46

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 19, 2014 (ML14268A305)
- B. Letter dated February 25, 2015 (ML15062A543)
- C. Letter dated August 12, 2015 (ML15225A556)
- D. Letter dated August 10, 2016 (ML16229A421)
- E. Letter dated June 8, 2017 (ML17163A160)
- F. Letter dated August 28, 2018 (ML18241A252)
- G. Letter dated September 20, 2018 (ML18290A542)
- H. Letter dated November 16, 2018 (ML18323A465)
- I. Letter dated June 13, 2019 (ML19178A066)
- J. Letter dated August 23, 2022 (ML22238A061)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 29, 2022

By: _____

Magdalena R. Gryglak
Region 3